Diplomat Pharmacy posts Q2 gain

FLINT, Mich. – For the second quarter ended June 30, Diplomat Pharmacy posted a revenue increase of 49% to $808 million. Total prescriptions dispsensed totaled 234,000, a 19% increase. 

 

The increase was the result of approximately $91 million of revenue from drugs that were new to the market or newly dispensed by Diplomat and approximately $109 million from the company's acquisitions. The remaining increase is primarily attributable to the impact of manufacturer price increases, a richer mix of high-priced drugs and payor mix changes.

 

“This was another great quarter for Diplomat," stated Phil Hagerman, Diplomat chairman and CEO. "We saw strong performance across the entire company as we continued to capitalize on our role as the nation’s largest independent specialty pharmacy.”